TableĀ 4

Summary of studies examining impact of surveillance on OAC outcomes

StudyYearTotal patients with OAC and GOJACNo of patients with cancer detected during surveillanceAssociation with earlier cancer stageAssociation with improved survivalGrade of evidence
Streitz et al7319937711p=0.006p=0.007III
Peters et al7419945217p=0.01p=0.05III
Van Sandick et al7519987016p=0.0001p=0.0029III
Corley et al7620022315p=0.02p=0.001III
Cooper et al77200216339.70%p<0.001*p<0.01III
Fountoulakis et al7820049117p=0.001p=0.008III
Rubenstain et al79200815525p=0.02HR 0.82 (95% CI 0.52 to 1.29)III
Cooper et al137200927548.10%p=0.001p=0.001III
  • *0.06 for cardia cancer.

  • GOJAC, gastro-oesophageal junction adenocarcinoma; HR, hazard ratio; OAC, oesophageal adenocarcinoma.